A phase 11 study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, JH | - |
dc.contributor.author | Whang, YM | - |
dc.contributor.author | Kim, BS | - |
dc.contributor.author | Choi, CW | - |
dc.contributor.author | Shin, SW | - |
dc.contributor.author | Kim, YH | - |
dc.contributor.author | Kim, JS | - |
dc.contributor.author | Goo, BH | - |
dc.date.accessioned | 2021-09-09T12:31:49Z | - |
dc.date.available | 2021-09-09T12:31:49Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2002-04-01 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/124385 | - |
dc.description.abstract | BACKGROUND. A Phase 11 study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline-resistant metastatic breast carcinoma (MBC). METHODS. Recurrent or progressed MBC within 12 months after anthracycline-based chemotherapy was defined as anthracycline-resistant. A 24-hour infusion of paclitaxel (175 mg/m(2)) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m(2)/day) with mesna (360 mg/m(2)/day) on Days 2- 4, were performed every 3 weeks. Twenty-one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5-fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients. RESULTS. Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2-24+) and 19+ months (range, 2-32+), respectively. Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. Other significant toxicities were peripheral neuropathy (n = 3), mucositis (n = 2), and liver dysfunction (n = 1). However, there was no chemo therapy-related death. CONCLUSIONS. Paclitaxel by 24-hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline-resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | JOHN WILEY & SONS INC | - |
dc.subject | CANCER | - |
dc.subject | TRIAL | - |
dc.subject | 5-FLUOROURACIL | - |
dc.subject | COMBINATION | - |
dc.subject | AGENTS | - |
dc.subject | TAXOL | - |
dc.title | A phase 11 study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, JH | - |
dc.identifier.doi | 10.1002/cncr.10431 | - |
dc.identifier.scopusid | 2-s2.0-0036534343 | - |
dc.identifier.wosid | 000174717700004 | - |
dc.identifier.bibliographicCitation | CANCER, v.94, no.7, pp.1925 - 1930 | - |
dc.relation.isPartOf | CANCER | - |
dc.citation.title | CANCER | - |
dc.citation.volume | 94 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1925 | - |
dc.citation.endPage | 1930 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordPlus | TAXOL | - |
dc.subject.keywordAuthor | anthracycline resistance | - |
dc.subject.keywordAuthor | breast carcinoma | - |
dc.subject.keywordAuthor | paclitaxel | - |
dc.subject.keywordAuthor | ifosfamide | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.